With a first-in-class compound marketers can potentially leverage long-lasting market advantages
To market a first-in-class compound is an amazing opportunity. With that built-in advantage, marketers can potentially leverage long-lasting market advantages, including the ability to:
Jay Carter, AbelsonTaylor | Senior VP, Director of Strategy Services
When done strategically, each of these facets helps your brand to remain the market leader once a competitor enters the arena. At AbelsonTaylor, we just finished one first-in-class launch, and are closing in on a second. But to be honest, we learned the lessons of building first-in-class brands by capitalizing on the opportunities afforded us when we launched some well-known follow-on compounds, which has occurred several times in the agency's history.
For Prevacid, even though Prilosec had been on the marketplace for six years, the total PPI marketplace was only about 11 percent of acid disease prescriptions. The goal was not to take business away from Prilosec, but instead to grow the overall PPI business by differentiating from Prilosec while reinforcing the definite advantages of a PPI.
I predict that several new followers coming soon will follow this strategy, as the time between first mover and second brand is now measured in months not years. For Actos, one of the key victories was the ability to shave the lead time that GSK's Avandia had on the brand to only a few months. The other key factor, decided upon before launch, was a long-term strategy to scientifically assess the role of the product in the cardiovascular component of diabetes. Clinical trials began early in the brand life cycle for Actos and resulted in clinicians feeling comfortable with its safety and efficacy even when Avandia, the other TZD in the marketplace, was buffeted by clinical concerns. Today, the life cycle plan for a brand is a part of the launch strategy ... and rightfully so.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.